MPC在肿瘤中的研究

Research of mitochondrial pyruvate carrier in tumors

线粒体丙酮酸载体(mitochondrial pyruvate carrier,MPC)位于线粒体内膜中,它可以将糖酵解中产生的丙酮酸运送到线粒体基质参与三羧酸(tricarboxylic acid,TCA)循环、糖异生以及脂质、氨基酸等代谢过程进而为机体提供能量。因此,MPC可以通过调控线粒体丙酮酸通量从而调控能量代谢。由于其在能量代谢中的重要作用,越来越多的证据表明,MPC可以作为代谢类疾病(包括癌症)的潜在靶点。最近研究发现,在多种癌症类型中,MPC表达的改变可以通过影响参与氧化磷酸化或糖酵解过程中的丙酮酸的比例诱导代谢重编程,进而影响肿瘤的增殖、迁移和侵袭能力以及对治疗的抵抗性。因此,本文将概述MPC在肿瘤发生、转移和治疗中的研究现状,以期为靶向MPC药物治疗肿瘤提供新的思路。

Mitochondrial pyruvate carrier(MPC)is located in the inner mitochondrial membrane,which can trans-port pyruvate produced in glycolysis to the mitochondrial matrix to participate in the metabolic processes such as tricar-boxylic acid(TCA)cycle,gluconeogenesis,lipids,and amino acids,thereby providing energy for the body.Therefore,MPC can regulate energy metabolism by regulating mitochondrial pyruvate flux.Due to its important role in energy me-tabolism,there is growing evidence that MPC can be a potential target for metabolic diseases,including cancer.Recent studies have found that in a variety of cancer types,alterations in MPC expression can affect the proliferation,migration and invasion of tumors,as well as their resistance to treatment,by affecting the participation in oxidative phosphoric acid.Therefore,this article summarized the research status of MPC in tumorigenesis,metastasis and treatment,in order to provide new ideas for targeted MPC drugs to treat tumors.